Your browser doesn't support javascript.
loading
Impact of Subsequent Therapies on Outcome of the FIRE-3/AIO KRK0306 Trial: First-Line Therapy With FOLFIRI Plus Cetuximab or Bevacizumab in Patients With KRAS Wild-Type Tumors in Metastatic Colorectal Cancer.
Modest, Dominik P; Stintzing, Sebastian; von Weikersthal, Ludwig Fischer; Decker, Thomas; Kiani, Alexander; Vehling-Kaiser, Ursula; Al-Batran, Salah-Eddin; Heintges, Tobias; Lerchenmüller, Christian; Kahl, Christoph; Seipelt, Gernot; Kullmann, Frank; Stauch, Martina; Scheithauer, Werner; Held, Svantje; Möhler, Markus; Jung, Andreas; Kirchner, Thomas; Heinemann, Volker.
Afiliação
  • Modest DP; Dominik P. Modest, Sebastian Stintzing, and Volker Heinemann, University Hospital Grosshadern; Andreas Jung and Thomas Kirchner, University of Munich, Munich; Dominik P. Modest, Sebastian Stintzing, Volker Heinemann, Andreas Jung, and Thomas Kirchner, German Cancer Consortium and German Cancer Resea
  • Stintzing S; Dominik P. Modest, Sebastian Stintzing, and Volker Heinemann, University Hospital Grosshadern; Andreas Jung and Thomas Kirchner, University of Munich, Munich; Dominik P. Modest, Sebastian Stintzing, Volker Heinemann, Andreas Jung, and Thomas Kirchner, German Cancer Consortium and German Cancer Resea
  • von Weikersthal LF; Dominik P. Modest, Sebastian Stintzing, and Volker Heinemann, University Hospital Grosshadern; Andreas Jung and Thomas Kirchner, University of Munich, Munich; Dominik P. Modest, Sebastian Stintzing, Volker Heinemann, Andreas Jung, and Thomas Kirchner, German Cancer Consortium and German Cancer Resea
  • Decker T; Dominik P. Modest, Sebastian Stintzing, and Volker Heinemann, University Hospital Grosshadern; Andreas Jung and Thomas Kirchner, University of Munich, Munich; Dominik P. Modest, Sebastian Stintzing, Volker Heinemann, Andreas Jung, and Thomas Kirchner, German Cancer Consortium and German Cancer Resea
  • Kiani A; Dominik P. Modest, Sebastian Stintzing, and Volker Heinemann, University Hospital Grosshadern; Andreas Jung and Thomas Kirchner, University of Munich, Munich; Dominik P. Modest, Sebastian Stintzing, Volker Heinemann, Andreas Jung, and Thomas Kirchner, German Cancer Consortium and German Cancer Resea
  • Vehling-Kaiser U; Dominik P. Modest, Sebastian Stintzing, and Volker Heinemann, University Hospital Grosshadern; Andreas Jung and Thomas Kirchner, University of Munich, Munich; Dominik P. Modest, Sebastian Stintzing, Volker Heinemann, Andreas Jung, and Thomas Kirchner, German Cancer Consortium and German Cancer Resea
  • Al-Batran SE; Dominik P. Modest, Sebastian Stintzing, and Volker Heinemann, University Hospital Grosshadern; Andreas Jung and Thomas Kirchner, University of Munich, Munich; Dominik P. Modest, Sebastian Stintzing, Volker Heinemann, Andreas Jung, and Thomas Kirchner, German Cancer Consortium and German Cancer Resea
  • Heintges T; Dominik P. Modest, Sebastian Stintzing, and Volker Heinemann, University Hospital Grosshadern; Andreas Jung and Thomas Kirchner, University of Munich, Munich; Dominik P. Modest, Sebastian Stintzing, Volker Heinemann, Andreas Jung, and Thomas Kirchner, German Cancer Consortium and German Cancer Resea
  • Lerchenmüller C; Dominik P. Modest, Sebastian Stintzing, and Volker Heinemann, University Hospital Grosshadern; Andreas Jung and Thomas Kirchner, University of Munich, Munich; Dominik P. Modest, Sebastian Stintzing, Volker Heinemann, Andreas Jung, and Thomas Kirchner, German Cancer Consortium and German Cancer Resea
  • Kahl C; Dominik P. Modest, Sebastian Stintzing, and Volker Heinemann, University Hospital Grosshadern; Andreas Jung and Thomas Kirchner, University of Munich, Munich; Dominik P. Modest, Sebastian Stintzing, Volker Heinemann, Andreas Jung, and Thomas Kirchner, German Cancer Consortium and German Cancer Resea
  • Seipelt G; Dominik P. Modest, Sebastian Stintzing, and Volker Heinemann, University Hospital Grosshadern; Andreas Jung and Thomas Kirchner, University of Munich, Munich; Dominik P. Modest, Sebastian Stintzing, Volker Heinemann, Andreas Jung, and Thomas Kirchner, German Cancer Consortium and German Cancer Resea
  • Kullmann F; Dominik P. Modest, Sebastian Stintzing, and Volker Heinemann, University Hospital Grosshadern; Andreas Jung and Thomas Kirchner, University of Munich, Munich; Dominik P. Modest, Sebastian Stintzing, Volker Heinemann, Andreas Jung, and Thomas Kirchner, German Cancer Consortium and German Cancer Resea
  • Stauch M; Dominik P. Modest, Sebastian Stintzing, and Volker Heinemann, University Hospital Grosshadern; Andreas Jung and Thomas Kirchner, University of Munich, Munich; Dominik P. Modest, Sebastian Stintzing, Volker Heinemann, Andreas Jung, and Thomas Kirchner, German Cancer Consortium and German Cancer Resea
  • Scheithauer W; Dominik P. Modest, Sebastian Stintzing, and Volker Heinemann, University Hospital Grosshadern; Andreas Jung and Thomas Kirchner, University of Munich, Munich; Dominik P. Modest, Sebastian Stintzing, Volker Heinemann, Andreas Jung, and Thomas Kirchner, German Cancer Consortium and German Cancer Resea
  • Held S; Dominik P. Modest, Sebastian Stintzing, and Volker Heinemann, University Hospital Grosshadern; Andreas Jung and Thomas Kirchner, University of Munich, Munich; Dominik P. Modest, Sebastian Stintzing, Volker Heinemann, Andreas Jung, and Thomas Kirchner, German Cancer Consortium and German Cancer Resea
  • Möhler M; Dominik P. Modest, Sebastian Stintzing, and Volker Heinemann, University Hospital Grosshadern; Andreas Jung and Thomas Kirchner, University of Munich, Munich; Dominik P. Modest, Sebastian Stintzing, Volker Heinemann, Andreas Jung, and Thomas Kirchner, German Cancer Consortium and German Cancer Resea
  • Jung A; Dominik P. Modest, Sebastian Stintzing, and Volker Heinemann, University Hospital Grosshadern; Andreas Jung and Thomas Kirchner, University of Munich, Munich; Dominik P. Modest, Sebastian Stintzing, Volker Heinemann, Andreas Jung, and Thomas Kirchner, German Cancer Consortium and German Cancer Resea
  • Kirchner T; Dominik P. Modest, Sebastian Stintzing, and Volker Heinemann, University Hospital Grosshadern; Andreas Jung and Thomas Kirchner, University of Munich, Munich; Dominik P. Modest, Sebastian Stintzing, Volker Heinemann, Andreas Jung, and Thomas Kirchner, German Cancer Consortium and German Cancer Resea
  • Heinemann V; Dominik P. Modest, Sebastian Stintzing, and Volker Heinemann, University Hospital Grosshadern; Andreas Jung and Thomas Kirchner, University of Munich, Munich; Dominik P. Modest, Sebastian Stintzing, Volker Heinemann, Andreas Jung, and Thomas Kirchner, German Cancer Consortium and German Cancer Resea
J Clin Oncol ; 33(32): 3718-26, 2015 Nov 10.
Article em En | MEDLINE | ID: mdl-26261259
Assuntos
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Colorretais / Protocolos de Quimioterapia Combinada Antineoplásica / Proteínas Proto-Oncogênicas / Proteínas ras Tipo de estudo: Clinical_trials Limite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: J Clin Oncol Ano de publicação: 2015 Tipo de documento: Article
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Colorretais / Protocolos de Quimioterapia Combinada Antineoplásica / Proteínas Proto-Oncogênicas / Proteínas ras Tipo de estudo: Clinical_trials Limite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: J Clin Oncol Ano de publicação: 2015 Tipo de documento: Article